Previous Close | 8.10 |
Open | 8.10 |
Bid | 8.28 x 1000 |
Ask | 8.50 x 1000 |
Day's Range | 8.10 - 8.39 |
52 Week Range | 2.60 - 9.84 |
Volume | |
Avg. Volume | 813,980 |
Market Cap | 888.143M |
Beta (5Y Monthly) | -0.49 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.81 |
Earnings Date | Aug 09, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.09 |
Alkermes, Geron, Immunocore and BELLUS Health have been highlighted in this Industry Outlook article.
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.
Vertex (VRTX) inaxaplin is being evaluated in a single-phase II/III pivotal study in patients with AMKD with two APOL1 mutations and proteinuric kidney disease.